Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombolytic Therapy | 5 | 2022 | 249 | 1.470 |
Why?
|
| Pulmonary Embolism | 4 | 2022 | 237 | 1.280 |
Why?
|
| Cardiac Tamponade | 2 | 2018 | 23 | 1.210 |
Why?
|
| Thrombosis | 6 | 2021 | 312 | 0.830 |
Why?
|
| Haemophilus influenzae | 2 | 2018 | 17 | 0.780 |
Why?
|
| Haemophilus Infections | 1 | 2018 | 8 | 0.600 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 21 | 0.590 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 46 | 0.570 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 233 | 0.570 |
Why?
|
| Renal Veins | 1 | 2017 | 29 | 0.550 |
Why?
|
| Catheterization, Central Venous | 1 | 2018 | 116 | 0.550 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 40 | 0.530 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 148 | 0.530 |
Why?
|
| Catheterization | 1 | 2017 | 240 | 0.490 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 100 | 0.490 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2022 | 177 | 0.490 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 374 | 0.450 |
Why?
|
| Anticoagulants | 3 | 2021 | 440 | 0.430 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 144 | 0.410 |
Why?
|
| Recycling | 1 | 2012 | 3 | 0.410 |
Why?
|
| Water Purification | 1 | 2012 | 4 | 0.410 |
Why?
|
| Waste Disposal, Fluid | 1 | 2012 | 3 | 0.410 |
Why?
|
| Filtration | 1 | 2012 | 27 | 0.410 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 295 | 0.400 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 289 | 0.400 |
Why?
|
| Fibrinolytic Agents | 4 | 2022 | 233 | 0.390 |
Why?
|
| Tissue Engineering | 1 | 2013 | 199 | 0.380 |
Why?
|
| Water Pollutants, Chemical | 1 | 2012 | 139 | 0.360 |
Why?
|
| Heparin | 2 | 2021 | 186 | 0.350 |
Why?
|
| Shock, Cardiogenic | 4 | 2016 | 126 | 0.340 |
Why?
|
| Cardiac Catheterization | 5 | 2016 | 317 | 0.340 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 2 | 2021 | 47 | 0.330 |
Why?
|
| Heart-Assist Devices | 5 | 2016 | 825 | 0.320 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2013 | 136 | 0.270 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1237 | 0.270 |
Why?
|
| Biomarkers | 4 | 2021 | 1814 | 0.270 |
Why?
|
| Exercise Therapy | 1 | 2007 | 88 | 0.270 |
Why?
|
| Nitric Oxide | 1 | 2007 | 281 | 0.250 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 435 | 0.250 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2019 | 198 | 0.230 |
Why?
|
| Stem Cells | 1 | 2007 | 381 | 0.230 |
Why?
|
| Humans | 28 | 2022 | 91073 | 0.220 |
Why?
|
| Aortic Valve | 2 | 2017 | 250 | 0.210 |
Why?
|
| Phantoms, Imaging | 3 | 2021 | 467 | 0.210 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 261 | 0.190 |
Why?
|
| Fibrinolysis | 1 | 2022 | 38 | 0.190 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2021 | 59 | 0.180 |
Why?
|
| Embolectomy | 1 | 2020 | 7 | 0.180 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2016 | 357 | 0.180 |
Why?
|
| Antithrombins | 1 | 2020 | 17 | 0.180 |
Why?
|
| Middle Aged | 16 | 2021 | 26555 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 91 | 0.170 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 521 | 0.170 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 47 | 0.170 |
Why?
|
| Female | 16 | 2021 | 47186 | 0.170 |
Why?
|
| Europe | 1 | 2020 | 329 | 0.170 |
Why?
|
| Elastic Modulus | 1 | 2019 | 38 | 0.160 |
Why?
|
| Ultrasonic Therapy | 1 | 2019 | 38 | 0.160 |
Why?
|
| Gels | 1 | 2019 | 51 | 0.160 |
Why?
|
| Aged | 12 | 2021 | 19574 | 0.160 |
Why?
|
| Lithotripsy | 1 | 2019 | 46 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2020 | 233 | 0.160 |
Why?
|
| Microbubbles | 1 | 2019 | 40 | 0.160 |
Why?
|
| Treatment Outcome | 8 | 2022 | 8436 | 0.160 |
Why?
|
| Recurrence | 2 | 2020 | 1170 | 0.160 |
Why?
|
| Cardiology | 1 | 2020 | 122 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2021 | 723 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2020 | 673 | 0.160 |
Why?
|
| Pericardiocentesis | 1 | 2018 | 5 | 0.150 |
Why?
|
| Acute Disease | 1 | 2020 | 855 | 0.150 |
Why?
|
| Pericarditis | 1 | 2018 | 15 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2019 | 113 | 0.150 |
Why?
|
| Monocytes | 1 | 2019 | 222 | 0.150 |
Why?
|
| Binge Drinking | 1 | 2018 | 15 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 162 | 0.150 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 94 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2018 | 299 | 0.140 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2015 | 69 | 0.140 |
Why?
|
| Phlebography | 1 | 2017 | 70 | 0.140 |
Why?
|
| Risk Assessment | 3 | 2020 | 2345 | 0.140 |
Why?
|
| Male | 16 | 2021 | 43249 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2020 | 594 | 0.130 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 58 | 0.130 |
Why?
|
| Heart Failure | 3 | 2016 | 1273 | 0.130 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 224 | 0.130 |
Why?
|
| Macrophages | 1 | 2019 | 589 | 0.130 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 30 | 0.130 |
Why?
|
| Disease Progression | 1 | 2020 | 1493 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1750 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 149 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 240 | 0.110 |
Why?
|
| Pericytes | 1 | 2013 | 14 | 0.110 |
Why?
|
| Adult | 8 | 2022 | 27147 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2016 | 307 | 0.110 |
Why?
|
| Calcium Carbonate | 1 | 2012 | 4 | 0.100 |
Why?
|
| Water Movements | 1 | 2012 | 8 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 251 | 0.100 |
Why?
|
| London | 1 | 2012 | 17 | 0.100 |
Why?
|
| Software | 1 | 2017 | 670 | 0.100 |
Why?
|
| Water Pollution | 1 | 2012 | 9 | 0.100 |
Why?
|
| Cell Communication | 1 | 2013 | 203 | 0.100 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2013 | 70 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 373 | 0.100 |
Why?
|
| Metals, Heavy | 1 | 2012 | 16 | 0.100 |
Why?
|
| Balloon Occlusion | 1 | 2012 | 30 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2016 | 281 | 0.100 |
Why?
|
| RNA Interference | 1 | 2013 | 378 | 0.100 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 123 | 0.100 |
Why?
|
| Water Supply | 1 | 2012 | 62 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 803 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2013 | 471 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 698 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2711 | 0.100 |
Why?
|
| Catheters | 2 | 2022 | 86 | 0.100 |
Why?
|
| Models, Chemical | 1 | 2012 | 179 | 0.100 |
Why?
|
| Cell Movement | 1 | 2013 | 793 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2021 | 290 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 669 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2022 | 997 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2013 | 739 | 0.080 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 618 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2021 | 433 | 0.080 |
Why?
|
| Septal Occluder Device | 3 | 2013 | 51 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1465 | 0.070 |
Why?
|
| Nitrites | 1 | 2007 | 32 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 37 | 0.070 |
Why?
|
| Phenotype | 1 | 2013 | 2480 | 0.070 |
Why?
|
| Exercise Test | 1 | 2007 | 168 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 228 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 231 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 112 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 1500 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 695 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 897 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2004 | 51 | 0.060 |
Why?
|
| Critical Illness | 2 | 2021 | 317 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 3716 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 481 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 167 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2022 | 1016 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 236 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 261 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 387 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3442 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 308 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2013 | 105 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2019 | 471 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6847 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2021 | 31 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2022 | 151 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 132 | 0.050 |
Why?
|
| Mice | 2 | 2013 | 11993 | 0.050 |
Why?
|
| Prosthesis Design | 2 | 2013 | 307 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2022 | 195 | 0.050 |
Why?
|
| Peptides | 1 | 2004 | 660 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 9399 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2022 | 255 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 284 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 241 | 0.040 |
Why?
|
| Animals | 3 | 2019 | 27783 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 681 | 0.040 |
Why?
|
| Acoustics | 1 | 2019 | 52 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 361 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 367 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 148 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 594 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 1216 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 785 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1713 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 52 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 123 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 291 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 758 | 0.030 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2015 | 82 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 826 | 0.030 |
Why?
|
| Heart Atria | 1 | 2016 | 285 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 566 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 51 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1263 | 0.030 |
Why?
|
| United States | 2 | 2016 | 7188 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 116 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2020 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 863 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2785 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 611 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1933 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1452 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1892 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2004 | 10 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2004 | 41 | 0.020 |
Why?
|
| Filgrastim | 1 | 2004 | 58 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 80 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 46 | 0.010 |
Why?
|
| Risk Factors | 2 | 2005 | 5608 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 161 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 296 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2891 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1564 | 0.010 |
Why?
|